Of mice and men: The relevance of transgenic mice Aβ immunizations to Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 4, Issue 5, 2002, Pages 431-434

  Roher, Alex E ^a   Kokjohn, Tyler A ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; COGNITIVE DEFECT; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; IMMUNIZATION; ISOMERISM; MOUSE; MOUSE STRAIN; NEUROPATHOLOGY; NONHUMAN; NOTE; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PURIFICATION; SENILE PLAQUE; SPECIES DIFFERENCE; TRANSGENIC MOUSE; VACCINATION;

EID: 0036813085     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2002-4509     Document Type: Note

References (25)

1. C. Janus and D. Westaway, Transgenic mouse models of Alzheimer's disease, Physiol Behavior 73 (2001), 873-886.
2. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandervert, S. Walker, M. Wogulis, T. Yednock, D. Games and P. Seubert, Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999), 173-177.
3. S.G. Younkin, Amyloid β vaccination: Reduced plaques and improved cognition, Nat Med 7 (2001), 18-19.
4. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang and G. Cole, Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice, Sci 274 (1996), 99-102.
5. Y.M. Kuo, T. Kokjohn, T.G. Beach, L.I. Sue, D. Brune, J.C. Lopez, W.M. Kalback, D. Abramowski, C. Sturchler-Pierrat, M. Staufenbiel and A.E. Roher, Comparitive analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains, J Biol Chem 276 (2001), 12991-12998.
6. W. Kalback, M.D. Watson, T.A. Kokjohn, Y.M. Kuo, N. Weiss, D.C. Luehrs, J. Lopez, D. Brune, S.S.Sisodia, M. Staufenbiel, M. Emmerling and A.E. Roher, APP transgenic mice Tg2576 accumulate Aβ peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques, Biochemistry 41 (2002), 922-928.
7. C. Sturchler-Pierrat, D. Abramowski, M. Duke, K.H. Wiederhold, C. Mistl, S. Rothacher, B. Ledermann, K. Burki, P. Frey, P.A. Paganetti, C. Waridel, M.E. Calhoun, M. Jucker, A. Probst, M. Staufenbiel and B. Sommer, Two amyloid precursor protein transgenic mouse A models with Alzheimer disease-like pathology, Proc Natl Acad Sci USA 94 (1997), 13287-13292.
8. A.E. Roher, J.D. Lowenson, S. Clarke, C. Wolkow, R. Wang, R.J. Cotter, I.M. Reardon, H.A. Zurcher-Neely, R.L. Heinrikson, M.J. Ball and B.D. Greenberg, Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease, J Biol Chem 268 (1993), 3072-3083.
9. A.E. Roher, K.C. Palmer, E.C. Yurewicz, M.J. Ball and B.D. Greenberg. Morphological and biochemical analyses of amyloid plaque core proteins purified form Alzheimer disease brain, J Neurochem 61 (1993), 1916-1926.
10. A.E. Roher, J.D. Lowenson, S. Clarke, A.S. Woods, R.J. Cotter, E. Gowing and M.J. Ball, β-amyloid 1-42 is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease, Proc Natl Acad Sci USA 90 (1993), 10836-10840.
11. E. Gowing, A.E. Roher, A.S. Woods, R.J. Cotter, M. Chaney, S.P. Little and M.J. Ball, Chemical characterization of Aβ 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease, J Biol Chem 296 (1994), 10987-10990.
12. A.E. Roher, M.O. Chaney, Y.M. Kuo, S.D. Webster, W.B. Stine, L.J. Haverkamp, A.S. Woods, R.J. Cotter, J.M. Tuohy, G.A. Krafft, B.S. Bonnell and M.R. Emmerling, Morphology and toxicity of Aβ (1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease, J Biol Chem 271 (1996), 20631-20635.
13. Y.M. Kuo, M.R. Emmerling, C. Vigo-Pelfrey, T. Kasunic, J.B. Kirkpatrick, G.H. Murdoch, M.J. Ball and A.E. Roher, Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains, J Biol Chem 271 (1996), 4077-4081.
14. Y.M. Kuo, M.R. Emmerling, A.S. Woods, R.J. Cotter and A.E. Roher, Isolation, chemical characterization, and quantitation of Aβ 3-pyroglutamyl peptides from neuritic plaques and vascular amyloid deposits, Biochem Biophys Res Comm 237 (1997), 188-191.
15. Y.M. Kuo, S. Webster, M.R. Emmerling, N. DeLima and A.E. Roher, Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Aβ peptides of Alzheimer's disease, Biochim Biophys Acta 1406 (1998), 291-298.
16. A.E. Roher, Y.M. Kuo, A.A. Roher, M.R. Emmerling and W.J. Goux, Chemical analysis of amyloid β protein in CAA, in: Cerebral Amyloid Angiopathy in Alzheimer's Disease and Related Disorders, M.M. Verbeek, ed., Kluwer Academic Publishers, the Netherlands, 2000, pp. 157-177.
17. M.L. Oster-Granite, D.L. McPhie, J. Greenan and R.L. Neve, Age-dependent neuronal and synaptic degeneration in mice transgenic for the C-terminus of amyloid precursor protein, J Neurosci 16 (1966), 6732-6741.
18. J. Berger-Sweeney, D.L. McPhie, J.A. Arters, J. Greenan, M.L. Oster-Granite and R.L. Neve, Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein, Mol Brain Res 66 (1999), 150-162.
19. Y.M. Kuo, F. Crawford, M. Mullan, T.A. Kokjohn, M.R. Emmerling, R.O. Weller and A.E. Roher, Elevated Aβ and apolipoprotein E in AβPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease, Mol Med 6 (2000), 430-439.
20. Y.M. Kuo, T.G. Beach, L.I. Sue, S. Scott, K.J. Layne, T.A. Kokjohn, W.M. Kalback, D.C. Luehrs, T.A. Vishnivetskaya, D. Abramowski, C. Sturchler-Pierrat, M. Staufenbiel and A.E. Roher, The evolution of Aβ peptide burden in APP23 transgenic mice: Implications for Aβ deposition in Alzheimer disease, Mol. Med. 7 (2001), 609-618.
21. B.J. Bacskai, S.T. Kajdacz, R.H. Christie, C. Carter, D. Games, P. Seubert, D. Schenk and B.T. Hyman, Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy, Nat Med 7 (2001), 369-372.
22. P. Das, M.P. Murphy, L.H. Younkin, S.G. Younkin and T.E. Golde, Reduced effectiveness of Aβ 1-42 immunization in APP transgenic mice with significant amyloid deposition, Neurobiol Aging 22 (2001), 721-727.
23. F. Bard, C. Cannon, R. Barbour, R.-L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk and T. Yednock, Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nat Med 6 (2000), 916-919.
24. D.M. Paresce, H. Chung and F.R. Maxfield, Slow degradation of aggregates of the Alzheimer's disease amyloid β-protein by microglial cells, J Biol Chem 272 (1997), 29390-29397.
25. H. Chung, M.I. Brazil, T.T. Soe and F.R. Maxfield, Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid β-peptide by microglial cells, J Biol Chem 274 (1999), 32301-32308.